Ultragenyx Pharmaceutical (RARE) EBIT (2016 - 2025)
Historic EBIT for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$170.9 million.
- Ultragenyx Pharmaceutical's EBIT fell 2947.49% to -$170.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$544.0 million, marking a year-over-year decrease of 154.01%. This contributed to the annual value of -$536.0 million for FY2024, which is 583.88% up from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its EBIT stood at -$170.9 million for Q3 2025, which was down 2947.49% from -$107.9 million recorded in Q2 2025.
- Ultragenyx Pharmaceutical's EBIT's 5-year high stood at -$82.8 million during Q2 2021, with a 5-year trough of -$225.1 million in Q3 2022.
- In the last 5 years, Ultragenyx Pharmaceutical's EBIT had a median value of -$136.6 million in 2022 and averaged -$134.6 million.
- As far as peak fluctuations go, Ultragenyx Pharmaceutical's EBIT tumbled by 15055.22% in 2022, and later surged by 3553.14% in 2023.
- Ultragenyx Pharmaceutical's EBIT (Quarter) stood at -$102.6 million in 2021, then plummeted by 41.99% to -$145.6 million in 2022, then grew by 16.19% to -$122.0 million in 2023, then fell by 0.19% to -$122.3 million in 2024, then crashed by 39.76% to -$170.9 million in 2025.
- Its EBIT was -$170.9 million in Q3 2025, compared to -$107.9 million in Q2 2025 and -$142.9 million in Q1 2025.